Dijon Pharmaceuticals completes $100 million round A financing.

Today' news from the industry, innovative pharmaceutical development and innovation enterprise Dizhe Pharmaceutical recently completed a $100 million round of A financing, this round of financing led by Lilly Asia Fund, Sequoia Capital, Tsany Innovation and Wuxi City two levels of government funds involved.
Based on public information, China Investment Innovation and AstraZeneca, a global pharmaceutical company, joined forces in October 2017 to establish a joint venture, Dijon Pharmaceuticals, based on AstraZeneca's Innovation Research and Development Center in Asia and Emerging Markets, to support Dr. Zhang Xiaolin and his team in their independent start-up.
company is committed to the exploration, development and commercialization of innovative drugs for small molecules.
Photo Source: Dijssjh Pharmaceuticals Website Over the past two years, the company has entered the international multi-center clinical trial phase.
AZD4205 is an efficient, gastrointestinally absorbed JAK1 selective inhibitor that is being developed for the treatment of inflammatory bowel disease (IBD).
DZD9008, an EGFR inhibitor that has potential anti-cancer efficacy in patients with non-small cell lung cancer who carry EGFR or HER2 gene no. 20 exon insertion mutations or other driving mutations.
addition, the company has a number of research projects.
according to the official website, its AZD3759 is intended to be developed for the treatment of patients with non-small cell lung cancer (NSCLC) who are positive for the appearance of a central nervous system (CNS) metastasis of the skin growth factor (EGFR) mutation.
Olapani is a polyphosphate adenosine nucleosine polymerase mechanism agent that blocks enzymes involved in repairing damaged DNA for the treatment of ovarian, breast and prostate cancer patients associated with BRCA gene defects.
.